Green Cross Juventas Investment Shows Gene Therapy Appetite
This article was originally published in PharmAsia News
South Korea's Green Cross Holdings has invested in the clinical-stage U.S. biotech firm Juventas Therapeutics in a bid to diversify into the cell and gene therapy sector. Along with Posco Capital, Green Cross led a $7.5 million investment in the Cleveland-based company, which focuses on developing non-viral gene therapies to treat advanced cardiovascular diseases.
You may also be interested in...
With big pharma on board, disappointments like the threatened EU market removal of pioneering Glybera and the Celladon trial failure give the field of gene therapy a bumpy ride after some major highs.
Investment in regenerative medicine has boomed over the past couple years, according to data presented at the Alliance for Regenerative Medicine's third annual Regen Med Investor Day, and all signs point to an even bigger year in 2015.
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.